Tracked deals
15
15 tracked deals across 2020-2025.
Tarrytown, NY, United States
For over 30 years, The IMA Group has enhanced the livelihood and productivity of individuals and organizations navigating health, work and disability while contributing to clinical advancements. IMA has two divisions: Evaluation Services (medical and psychological evaluations and ancillary services for government agencies, commercial insurers/TPAs, and corporate clients) and a Clinical Research Site Network specializing in Phase II–IV clinical trials using a site-based, hybrid and decentralized study approach.
Tracked deals
15
15 tracked deals across 2020-2025.
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
12 buyout · 3 addon
Last 5 years
Supporting Data
Showing the 12 most recent of 15 tracked deals for The IMA Group.
The IMA Group (IMA Clinical Research), a PE-backed national clinical research platform, has acquired Chicago Research Center (CRC), an independent clinical research site in Chicago specializing in CNS and sleep disorder trials. The deal expands IMA's geographic footprint and capabilities—marking its first dedicated sleep research site—and will keep CRC's leadership and staff in place to support Phase I–IV trials.
The IMA Group has acquired Medical Research Network (MRN) LLC, a New York City–based clinical research site specializing in psychiatry and neurology (CNS) trials. MRN will continue to operate under its current name and leadership (founder and CEO Dr. Michael R. Liebowitz), and the deal expands IMA's CNS footprint with its first East Coast CNS-dedicated location.
The IMA Group has acquired Pontum Health, a Seattle‑area provider of Social Security Disability and related consultative evaluations. The acquisition extends IMA's Evaluation Services coverage further into the Pacific Northwest—adding Alaska and Oregon and strengthening presence in Washington—while Pontum's leadership team will remain in place; financial terms were not disclosed.
The IMA Group (IMA Clinical Research) has acquired Accelemed Research Institute, a clinical research site in Austin, Texas, expanding IMA's footprint in the Southwest to more than 20 sites. The acquisition deepens IMA's capabilities in multi-therapeutic clinical trials—particularly cardiometabolic and GI indications—and keeps Accelemed operating under its current name with existing leadership retained.
The IMA Group’s clinical research division, IMA Clinical Research, has acquired Clinical Trials of America (CTA), adding 10 site locations (four independent and six embedded) and expanding IMA’s reach in Louisiana and North Carolina. CTA will continue to operate under existing leadership, and the deal increases IMA’s clinical network and therapeutic capabilities to better serve sponsors and CROs; terms were not disclosed.
The IMA Group has acquired Mollie Kallen Case Management (MKCM), expanding IMA’s national case management capabilities within its growing Payer Services division. The acquisition strengthens IMA’s presence in key states including Florida, Georgia, Illinois, Michigan and Ohio; MKCM will retain its leadership and continue operating under its current name.
The IMA Group's Clinical Research division acquired Amici Clinical Research, adding two New Jersey clinical trial sites (Raritan and Hoboken) to IMA's network. The acquisition expands IMA's Northeast footprint and therapeutic capabilities across areas including fatty liver, cardiovascular, pulmonary and neurologic diseases, and supports site-based, hybrid and decentralized trials.
The IMA Group has acquired Redlink, Inc., a regional provider of Social Security Disability consultative examinations operating in the Western United States. The deal expands IMA's service area into seven additional states and strengthens its presence in western and rural markets; financial terms were not disclosed and Redlink's leadership will remain in place.
The IMA Group (IMA Clinical Research) has acquired Exemplar Research, Inc., a community-based specialty research clinic serving the North Central region of West Virginia. The acquisition expands IMA's clinical trial network and broadens access to diverse patient populations and therapeutic capabilities in underserved areas.
The IMA Group (IMA) acquired Diagnostics Research Group (DXRG), a San Antonio-based clinical research site, expanding IMA's Clinical Research Division into South Texas and adding DXRG's multi-specialty trial capabilities. Financial terms were not disclosed and DXRG will continue operating under its current name with existing leadership and staff retained.
The IMA Group has acquired Albuquerque Neuroscience, Inc., a clinical research site specializing in central nervous system (CNS) and general medical condition trials. The acquisition expands IMA Clinical Research's national footprint and deepens its capabilities in psychiatry, Alzheimer's disease and other neuropathic therapeutic areas; financial terms were not disclosed.
The IMA Group, a technology-enabled provider of medical and psychological screening and evaluation services, has acquired MedPlus Disability Evaluations, a regional provider of Social Security Disability consultative examinations. The acquisition expands IMA's geographic footprint by adding MedPlus's operations across an additional seven states and broadens IMA's portfolio of disability and specialty evaluation services.
Turn tracked acquisition activity into an outreach-ready buyer list.